라파마이신/mTOR 상호 작용을 연구하기 위한 반정량적 약물 선호도 반응 형 표적 안정성(DARTS) 분석

Executive Industry Relevance

The enhanced DARTS assay provides a label-free, native-state approach to validate small-molecule target engagement, supporting early-stage target de-risking. By quantifying binding affinity through proteolytic and dose-dependent curves, it enables mechanistic confidence in hit-to-lead progression. This method aids in prioritizing compounds with validated target interactions, reducing attrition due to false positives in downstream screening.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Confirms direct target engagement of small molecules like rapamycin with mTOR in native lysates.
• Operational Value: Uses unmodified compounds, avoiding artifacts from tags or labels that may alter binding.
• Predictive Value: Enables affinity estimation to triage hits based on target residence and stability shifts.

Screening & Assay Development

• Assay Readiness: Generates quantitative proteolytic and dose-response curves for hit confirmation.
• Reproducibility: Standardized workflow with defined pronase titration and inhibitor quench points.
• Scalability: Compatible with multi-well formats for testing compound libraries against purified or cellular targets.

Translational & Preclinical Research

• Translational Continuity: Validated target engagement in cellular lysates supports extrapolation to intact systems.
• Mechanistic De-risking: Distinguishes specific binding from nonspecific proteolysis inhibition via dose-dependent stabilization.
• Preclinical Alignment: Confirmed mTOR-rapamycin interaction provides a benchmark for pathway-targeted compound evaluation.

Pipeline & Workflow Integration

The assay fits between primary hit confirmation and lead optimization, offering biophysical validation before cellular functional assays.

• Discovery Biology: Tests target hypothesis by measuring ligand-induced stability shifts in native protein pools.
• Screening: Confirms target engagement of hits from biochemical or phenotypic screens using endogenous protein.
• Analytics: Provides affinity estimates from dose-dependence curves and stability changes from proteolytic profiles.
• Translational Research: Uses cellular lysates to maintain native protein complexes and post-translational states.
• Enterprise Reuse: Platform adaptable to diverse targets and ligands without reagent redesign.

Operational & Enterprise Impact

• Scientific Value: Direct measurement of target stabilization enables objective assessment of ligand efficacy.
• Operational Value: Simple workflow using standard lysis, protease digestion, and Western blot infrastructure.
• Strategic Value: Reduces false advancement by confirming target binding early in the discovery cascade.
• Portfolio Impact: Supports go/no-go decisions based on quantitative target engagement metrics.

Implementation Considerations

• Requires expertise in Western blotting and quantitative band analysis.
• Dependent on access to pronase and protease inhibitor cocktails for controlled digestion.
• Needs standardization across labs for consistent pronase:protein ratios and incubation times.
• Adaptation to membrane or complex targets may require optimization of lysis conditions.
• Practical limitation: Semi-quantitative nature requires replicate runs for reliable affinity estimation.

Biopharma FAQs